Earn-out Consideration and Issue of Equity.

Abingdon Health plc

("Abingdon Health", the "Group" or the "Company")

Earn-out Consideration and Issue of Equity

York, UK and Madison, WI, USA, 19 May 2026: Abingdon Health plc (AIM: ABDX) (OTCQB: ABDXF), a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, announces that the earn-out conditions in respect of its acquisition of IVDeology Holdings Ltd ("IVDeology"), originally announced on 7 May 2024 (the "Acquisition"), have been satisfied.

Pursuant to the terms of the share purchase agreement ("SPA"), earn-out consideration of £200,000 (the "Earn-out Consideration") has become payable following the achievement of the maximum revenue target for the two-year earn-out period following acquisition. 

Accordingly, the Earn-out Consideration will be satisfied by the issue of 1,673,640 new ordinary shares in the Company ("Earn-out Shares") to the vendors, Stuart Angell and Nancy Consterdine, in equal proportions.

The number of Earn-out Shares to be issued has been determined by reference to an issue price calculated as the average of the closing middle market price of the Company's ordinary shares for the five dealing days from 12 May to 18 May 2026 (inclusive), being the five dealing days ending on the dealing day immediately prior to the settlement date, in accordance with the terms of the SPA (the "Issue Price"). 

The Earn-out Shares will rank pari passu in all respects with the Company's existing ordinary shares.

In accordance with the terms of the SPA, the Earn-out Shares will be subject to lock-in and orderly market provisions, comprising a 12-month lock-in period followed by a 12-month orderly market arrangement.

Application has been made for the Earn-out Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective at 8.00 a.m. on 26 May 2026.

Total Voting Rights

Following Admission, the Company's issued share capital will consist of 252,751,490 ordinary shares of 0.025 pence each, each with one voting right. The Company does not hold any shares in treasury.

Therefore, the total number of voting rights in the Company will be 252,751,490. This figure may be used by shareholders as the denominator for the calculations by which they determine if they are required to notify their interest in, or a change to their interest in, the Company's share capital under the FCA's Disclosure Guidance and Transparency Rules.

Any shareholders wishing to keep up to date with Abingdon Health news, please email abingdon@walbrookpr.com

Enquiries:

About Abingdon Health

Abingdon Health Group is a leading med-tech contract service provider offering its services to an international customer base.  

The Group's CDMO (Contract Development and Manufacturing Organisation) expertise offers lateral flow product development, regulatory strategy support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format.  Abingdon Health has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing, from initial concept through to routine manufacturing; from idea to commercial success.

Abingdon's regulatory services companies, Compliance Solutions (Life Sciences) and IVDeology, provide a broad range of regulatory services to the in vitro diagnostic and wider medical device industry, to support customers in bringing products to market across a range of territories including the USA, EU and the UK. Its consultancy services range from design, implementation and maintenance of quality management systems, preparation of technical files for regulatory approvals, part-time and interim management support, auditing both internal and external, management reviews and presentations, training and mentoring.  The Company's subsidiary, Abingdon Analytical Ltd, offers analytical testing and performance evaluation to generate the required technical and data for regulatory approval for lateral flow and other in vitro diagnostic assays from its Doncaster, England facilities.

Founded in 2008, Abingdon Health is headquartered in York, England with laboratories in Doncaster, England and laboratories and commercial offices in Madison, Wisconsin, USA.

Abingdon Health's brochures outlines the comprehensive support the Group can now provide to its international customers.  For more information visit: www.abingdonhealth.com.

LEI - 213800XFI4WV3FBILO20